Nuwellis (NASDAQ:NUWE) & Vicarious Surgical (NYSE:RBOT) Critical Analysis

Nuwellis (NASDAQ:NUWE) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 9.5% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Nuwellis has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Vicarious Surgical has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Nuwellis and Vicarious Surgical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1	0	0	0	1.00
Vicarious Surgical	1	2	0	0	1.67

Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 677.78%. Given Vicarious Surgical’s stronger consensus rating and higher probable upside, analysts clearly believe Vicarious Surgical is more favorable than Nuwellis.

Profitability

This table compares Nuwellis and Vicarious Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Vicarious Surgical	N/A	-184.13%	-112.50%

Earnings and Valuation

This table compares Nuwellis and Vicarious Surgical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27 million	0.25	-$17.52 million	($64.02)	-0.01
Vicarious Surgical	N/A	N/A	-$63.22 million	($6.69)	-0.13

Nuwellis has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Summary

Vicarious Surgical beats Nuwellis on 9 of the 12 factors compared between the two stocks.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.